Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Operations (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Cash from Operations data on record, last reported at 30366000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 40.49% year-over-year to 30366000.0; the TTM value through Sep 2025 reached 52846000.0, up 162.68%, while the annual FY2024 figure was 86851000.0, 7.13% down from the prior year.
  • Cash from Operations reached 30366000.0 in Q3 2025 per STOK's latest filing, down from 25422000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 131827000.0 in Q1 2025 and bottomed at 30366000.0 in Q3 2025.
  • Average Cash from Operations over 4 years is 8249666.67, with a median of 21615000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: crashed 165.73% in 2023, then surged 636.62% in 2025.
  • A 4-year view of Cash from Operations shows it stood at 22373000.0 in 2022, then increased by 7.71% to 20649000.0 in 2023, then fell by 12.32% to 23193000.0 in 2024, then plummeted by 30.93% to 30366000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 30366000.0 in Q3 2025, 25422000.0 in Q2 2025, and 131827000.0 in Q1 2025.